Generic drug giant Mylan N.V. will pay $30 million to settle Securities and Exchange Commission charges over “false and misleading” public filings involving the company’s popular EpiPen.
In a regulatory filing in July, Mylan, which has offices in Cecil and the Netherlands, disclosed a tentative agreement over the charges with the SEC.
According to the SEC complaint, Mylan classified EpiPen as a generic drug under the Medicaid Drug Rebate Program, which resulted in Mylan paying much lower rebates to the government than if EpiPen had been classified as a branded drug. Drugmakers routinely offer product rebates to customers.
The Centers for Medicare and Medicaid Services informed Mylan in October 2014 that EpiPen was misclassified as a generic drug, prompting a Department of Justice probe the following month.
For two years, the DOJ investigated whether Mylan overcharged Medicaid by hundreds of millions of dollars for the injectible drug used to treat severe allergic reactions, according to the SEC. The EpiPen is the company’s largest revenue and profit generating product.
That probe resulted in a $465 million settlement with the DOJ in 2016, but Mylan hadn’t disclosed the investigation to investors before then and didn’t accrue funds to cover the loss, the SEC said.
Read More
“As alleged in our complaint, investors were kept in the dark about Mylan’s EpiPen misclassification and the potential loss Mylan faced as a result of the pending investigations into the misclassification,” Antonia Chion, associate director of the SEC’s Division of Enforcement, said in a prepared statement.
The SEC said Mylan’s public filings in 2014 and 2015 were “false and misleading” because they failed to disclose that federal officials had informed the company of the drug misclassification.
Mylan agreed to pay $30 million to settle the charges without admitting or denying guilt.
Company officials were not immediately available.
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.